These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38574518)

  • 1. Immunomodulatory effect of Unani polyherbal formulation - Tiryaq Wabai in mild to moderate COVID-19 patients - A randomized placebo-controlled clinical trial.
    Kumar A; Khan MS; Haque ZU; Rai A; Fazil M; Rabbani G
    J Ayurveda Integr Med; 2024; 15(2):100903. PubMed ID: 38574518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Unani polyherbal formulation (Tiryaqe wabai) as an immunostimulator in elderly persons.
    Nigar Z; Itrat M
    Anc Sci Life; 2013 Oct; 33(2):119-22. PubMed ID: 25284946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical review of
    Anwar N; Ahmed NZ; Fathima AF; Khan AA
    J Herb Med; 2023 Jun; 39():100653. PubMed ID: 37073363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the Unani Regimen as an Add-On to Standard Treatment in Hospitalised RT-PCR-Confirmed Mild to Moderate COVID-19 Patients: An Open-Label Randomized Controlled Trial.
    Kishore J; Kumar R; Nazli T; Ahmad A; Kumar P; Khan AA
    Cureus; 2023 May; 15(5):e38574. PubMed ID: 37284399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding
    Alam MA; Quamri MA; Ayman U; Sofi G; Renuka BN
    J Complement Integr Med; 2021 Jan; 18(3):469-476. PubMed ID: 33544515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial.
    Srivastava A; Rengaraju M; Srivastava S; Narayanan V; Gupta V; Upadhayay R; Kumar J; Parameswaran S; KanakavalliKadarkarai ; AarthiVelmurugan
    Trials; 2021 Aug; 22(1):570. PubMed ID: 34454572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationalistic approach in COVID-19 prevention through intervention of Unani medicine prevalent in epidemic - A review.
    Khan F; Ansari AN; Nayab M
    J Herb Med; 2021 Dec; 30():100515. PubMed ID: 34722133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A computational study on active constituents of
    Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
    J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Evaluation of a Topical Unani Polyherbal Formulation in the Management of Photodamaged Facial skin: An open-label Standard Controlled Trial.
    Bibi C; Nigar Z
    Altern Ther Health Med; 2024 Mar; 30(3):16-23. PubMed ID: 38518171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ and CD8+ cell counts are significantly correlated with absolute lymphocyte count in hospitalized COVID-19 patients: a retrospective study.
    Liana P; Samosir AP; Sari NP; Andriani RAL; Verdiansah V; Hidayatullah H; Ahmad Z; Umar TP
    PeerJ; 2023; 11():e15509. PubMed ID: 37377785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial.
    Wijewickrama A; Idampitiya D; Karunarathne M; Pahalagamage S; Sellahewa K; Govindapala D; Kalambarachchi H; Sooriyarachchi R; Chandrarathne N; Goonaratna C; Perera J
    J Ethnopharmacol; 2024 Apr; 323():117535. PubMed ID: 38070837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19.
    Fu HY; Luo Y; Gao JP; Wang L; Li HJ; Li X; Xue L; Tang XQ; Li HW; Du YR
    Biomed Res Int; 2020; 2020():2854186. PubMed ID: 33015160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells.
    Abbadessa G; Maida E; Miele G; Lavorgna L; Marfia GA; Valentino P; De Martino A; Cavalla P; Bonavita S
    Mult Scler Relat Disord; 2022 Apr; 60():103740. PubMed ID: 35305426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.